Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study

No abstract is available for this paper.

• Publication year

  2009

• Venue

  International ophtalmology

• Publication date

  2009-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10792-008-9221-7PMID 18418553
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients

  2008cited by this paper
• Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.

  2007cited by this paper
• Penetration of bevacizumab through the retina after intravitreal injection in the monkey.

  2007cited by this paper
• Pharmacokinetics of Intravitreal Bevacizumab in Humans

  2007cited by this paper
• Reproducibility of dipping/nondipping pattern in untreated essential hypertensive patients: impact of sex and age

  2007cited by this paper
• Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.

  2007cited by this paper
• The eye in hypertension.

  2007cited by this paper
• Intravitreal Ranibizumab and Bevacizumab: A Review of Risk

  2007cited by this paper
• Short-term reproducibility of a non-dipping pattern in type 2 diabetic hypertensive patients

  2006cited by this paper
• Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure.

  2006cited by this paper
• Ranibizumab in neovascular age-related macular degeneration

  2006influential reference
• Ranibizumab for neovascular age-related macular degeneration.

  2006cited by this paper
• The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide

  2006cited by this paper
• DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

  2006cited by this paper
• Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.

  2005cited by this paper
• Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research.

  2005cited by this paper
• Hypertension associated with bevacizumab.

  2005cited by this paper
• Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research.

  2005cited by this paper
• White-coat hypertension in adults

  2005cited by this paper
• Pulse pressure, heart rate, and drug treatment of hypertension

  2004cited by this paper
• Stress-Induced Blood Pressure Reactivity and Silent Cerebrovascular Disease

  2004cited by this paper
• Bevacizumab for Patients with Metastatic Renal Cancer

  2004cited by this paper
• Angiogenic growth factors and hypertension

  2004cited by this paper
• Reproducibility of blood pressure variability, white‐coat effect and dipping pattern in untreated, uncomplicated and newly diagnosed essential hypertension

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Blood pressure and cardiovascular risks: implications of the presence or absence of a nocturnal dip in blood pressure.

  2003cited by this paper
• The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

  2003cited by this paper
• Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

  2003cited by this paper
• Comparison of Circadian Rhythm Characteristics of Blood Pressure and Heart Rate in Patients Before and After Elective Coronary Artery Bypass Surgery

  2003cited by this paper
• The VIVA Trial Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis

  2003cited by this paper
• Comparisons of the Intraocular Tissue Distribution, Pharmacokinetics, and Safety of 125I-Labeled Full-Length and Fab Antibodies in Rhesus Monkeys Following Intravitreal Administration

  1999cited by this paper
• Cardiac and Arterial Target Organ Damage in Adults with Elevated Ambulatory and Normal Office Blood Pressure

  1999cited by this paper
• Clinical implication of VEGF serum levels in cirrhotic patients with or without portal hypertension.

  1999cited by this paper
• Effects of vascular endothelial growth factor on hemodynamics and cardiac performance.

  1996cited by this paper
• Ambulatory blood pressure monitoring in the diagnosis of hypertension.

  1995cited by this paper
• Factors affecting ambulatory blood pressure reproducibility. Results of the HARVEST Trial. Hypertension and Ambulatory Recording Venetia Study.

  1994cited by this paper
• Long‐term reproducibility of ambulatory blood pressure

  1994cited by this paper
• Cost effectiveness of 24-hour ambulatory blood pressure monitoring in evaluation and treatment of essential hypertension.

  1994cited by this paper
• Ambulatory pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension

  1994cited by this paper
• National Standard for Measurement of Resting and Ambulatory Blood Pressures With Automated Sphygmomanometers

  1993cited by this paper
• Reproducibility of ambulatory and clinic blood pressure measurements in elderly hypertensive subjects

  1993cited by this paper
• Relationship between initial cardiovascular structural changes and daytime and nighttime blood pressure monitoring.

  1992cited by this paper
• Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension.

  1990cited by this paper
• Effects of noninvasive ambulatory blood pressure measuring devices on blood pressure.

  1990cited by this paper
• The reproducibility of average ambulatory, home, and clinic pressures.

  1988cited by this paper
• Ambulatory blood pressure monitoring does not interfere with the haemodynamic effects of sleep.

  1985cited by this paper

• Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an update

  2019influential citation
• Short-term effects of intravitreal ranibizumab and bevacizumab administration on 24-h ambulatory blood pressure monitoring recordings in normotensive patients with age-related macular degeneration

  2017cites this paper
• Review of the latest treatments for retinopathy of prematurity: laser photo-ablation versus intravitreal anti-VEGF agents in the management of high-risk pre-threshold (type 1) disease

  2015cites this paper
• Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection.

  2015cites this paper
• Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview

  2014cites this paper
• Retinal Blood Flow Velocity in Patients with Age-Related Macular Degeneration

  2014cites this paper
• THE EFFECT OF INTRAVITREAL AVASTIN ON SYSTEMIC BLOOD PRESSURE IN CONTROLLED HYPERTENSIVE PATIENTS

  2013cites this paper
• Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials.

  2013cites this paper
• An evidence-based review of vascular endothelial growth factor inhibition in pediatric retinal diseases: part 2. Coats' disease, best disease, and uveitis with childhood neovascularization.

  2013cites this paper
• Influence of intravitreal injection of bevacizumab on systemic blood pressure changes in patients with exudative form of age-related macular degeneration.

  2013cites this paper
• The effect of intravitreal bevacizumab (Avastin) injection on retinal blood flow velocity in patients with choroidal neovascularization

  2012cites this paper
• Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both?

  2012cites this paper
• Comparison of Systemic Adverse Events Associated with Intravitreal Anti-VEGF Injection: Ranibizumab versus Bevacizumab

  2012cites this paper
• Reduction of vascular endothelial growth factor a in human breast milk after intravitreal injection of bevacizumab but not ranibizumab.

  2012cites this paper
• Concentrations of unbound bevacizumab in the aqueous of untreated fellow eyes after a single intravitreal injection in humans

  2012influential citation
• An evidence-based meta-analysis of vascular endothelial growth factor inhibition in pediatric retinal diseases: part 1. Retinopathy of prematurity.

  2012cites this paper
• Pegaptanib zur Behandlung des diabetischen Makulaödems Ergebnisse der Phase-III-Studie - Zellbiologische und physiologische Aspekte der Anti-VEGF-Behandlung

  2011cites this paper
• A SYSTEMATIC REVIEW OF THE ADVERSE EVENTS OF INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS

  2011cites this paper
• Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.

  2011cites this paper
• Pegaptanib zur Behandlung des diabetischen Makulaödems

  2011cites this paper
• Blood pressure changes after intravitreal bevacizumab in patients grouped by ocular pathology

  2010cites this paper
• Identifying systemic safety signals following intravitreal bevacizumab: systematic review of the literature and the Canadian Adverse Drug Reaction Database.

  2010cites this paper
• Blood pressure changes after intravitreal bevacizumab in patients grouped by ocular pathology

  2010cites this paper
• Loss of nocturnal blood pressure fall in various extrapyramidal syndromes

  2009cites this paper
• A PROSPECTIVE STUDY OF BLOOD PRESSURE AND INTRAOCULAR PRESSURE CHANGES IN HYPERTENSIVE AND NONHYPERTENSIVE PATIENTS AFTER INTRAVITREAL BEVACIZUMAB INJECTION

  2009cites this paper
• Off-Label Use of Bevacizumab for the Treatment of Age-Related Macular Degeneration

  2009cites this paper
• Diabetic macular oedema : the role of steroids and VEGF

  2009cites this paper
• Chancen und Risiken der Anti-VEGF-Therapie

  2008cites this paper